We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » J&J Gets Complete Response Letter For Once-Daily HIV Prezista Dose
J&J Gets Complete Response Letter For Once-Daily HIV Prezista Dose
June 1, 2012
The FDA has handed Johnson & Johnson (J&J) a complete response letter on its sNDA for a once-daily formulation of HIV drug Prezista.